Gilead will lose U.S. exclusivity for big-selling HIV drug Truvada later this year. (Gilead China)
2019 revenue: $22.45 billion 2018 revenue: $22.13 billion Headquarters: Foster City, California
Helped by the best-selling launch of triple-drug HIV therapy Biktarvy, Gilead Sciences treaded water in 2019, with the rest of its drug portfolio turning in an up-and-down performance. Gilead raked in $22.45 billion in net revenue in 2019, a meager 1.5% increase from the prior year.
First, the bright spot: Biktarvy's blockbuster HIV launch reeled in $4.74 billion in sales in 2019, skyrocketing from $1.18 billion the year before––a whopping 300% increase.